Neurohumoral and hemodynamic effects of the selective endothelin antagonist darusentan in advanced chronic heart failure

Journal of Heart and Lung Transplantation

Volumn 23, Issue 1, 2004, Pages 20-27

  Bergler Klein, Jutta ^a,b   Pacher, Richard ^a   Berger, Rudolf ^a   Bojic, Anda ^a   Stanek, Brigitte ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIG ENDOTHELIN 1; BRAIN NATRIURETIC PEPTIDE; DARUSENTAN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN A RECEPTOR ANTAGONIST; FUROSEMIDE; NEUROHORMONE; NITRIC ACID DERIVATIVE; PLACEBO; SPIRONOLACTONE;

ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ELECTIVE SURGERY; FEMALE; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SWAN GANZ CATHETER; VERTIGO;

EID: 0346374596     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(03)00062-7     Document Type: Article

References (30)

1. Cleland J.G.F. Heart failure a medical hydra . Lancet. 352:(suppl I):1998;1-2.
2. Am J Cardiol. 83:1999;1A-38A.
3. Pacher R., Bergler-Klein J., Globits S., Teufelsbauer H., Schuller M., Krauter A., Ogris E., Rödler S., Wutte M., Hartter E. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol. 71:1993;1293-1299.
4. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
5. Kiowski W., Sütsch G., Hunziker P., Muller P., Kim J., Oechslin E., Schmitt R., Jones R., Bertel O. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
6. Battistini B., Dussault P. Blocking of the endothelin system the development of receptor antagonists . Pulmon Pharmacol. 11:1998;97-112.
7. McMurray J.J., Ray S.G., Abdullah I., Dargie H.D., Morton J.J. Plasma endothelin in chronic heart failure. Circulation. 85:1992;1374-1379.
8. Cody R.J., Haas G.J., Binkley P.F., Capers Q., Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 85:1992;504-509.
9. Dupuis J., Goresky C.A., Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo exclusive role of ETB receptors . J Appl Physiol. 81:1996;1510-1515.
10. B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 89:1994;1203-1208.
11. Sutsch G., Kiowski W., Yan X.W., Hunziker P., Christen S., et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 98:1998;2262-2268.
12. Packer M., Swedberg K., McMurray J., Kiowski W., Krum H., Massie B., Caspi A., Cohehn-Solai A., Kostuk W., Levine B., Rizzon P., Soler J., Charlon V. Multicenter, double blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure results of the REACH-1 trial . Abstract from 71st Scientific Session of the American Heart Association. 1998.
13. A receptor blockade in patients with congestive heart failure. J Am Coll Cardiol. 35:2000;1745-1752.
14. Ruschitzka F., Pacher R., Enseleit F., et al. Chronic selective ETA receptor blockade in congestive heart failure. The Heat Trial (Heart Failure ETA Receptor Blockade Trial). Abstracts from Scientific Sessions 2000 of the American Heart Association. Circulation. 102:((18) Suppl II):2000;II-593.
15. Bergler-Klein J., Pacher R., Berger R., Bojic A., Stanek B. Neurohumoral and hemodynamic effets of the selective endothelin antagonist LU 135252 in advanced heart failure. Abstracts from Scientific Sessions 2000 of the American Heart Associaton. Circulation. 102:((18) Suppl II):2000;II-592.
16. Pacher R., Stanek B., Hülsmann M., Koller-Strametz J., Berger R., Schuller M., et al. Prognostic impact of big endothelin-1 plasma concentrations as compared to invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 27:1996;633-641.
17. Hülsmann M., Stanek B., Frey B., Sturm B., Putz D., Kos T., Berger R., Woloszczuk W., Maurer G., Pacher R. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol. 32:1998;1695-1700.
18. Stanek B., Frey B., Berger R., Hartter E., Pacher R. Value of sequential big endothelin plasma concentrations to predict rapid worsening of chronic heart failure. Transplant Proc. 31:1999;155-157.
19. Zolk O., Quattek J., Sitzler G., Schrader T., Nickenig G., Schnabel P., Shimada K., Takahashi M., Böhm M. Expression of endothelin-1, endothelin-converting enzyme and endothelin receptors in chronic heart failure. Circulation. 99:1999;2118-2123.
20. A receptor blockade trial (HEAT). Circulation. 106:2002;2666-2672.
21. Richard A.M., Nicholls M.G., Yandle T.G., Frampton C., Espiner E.A., Turner J.G., Buttimore R.C., Lainchbury J.G., Elliott J.M., Ikram H., Crozier I.G., Smyth D.W. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 97:1998;1921-1929.
22. Richards A.M., Doughty R., Nicholls M.G., Macmahon S., Ikram H., Sharpe N., Espiner E.A., Frampton C., Yandle T.G. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation. 99:1999;786-792.
23. Arakawa N., Nakamura M., Aoki H., Hiramori K. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol. 27:1996;1656-1661.
24. Omland T., Aakvaag A., Bonarjee V.VS., Caidahl K., Lie R.T., Nilsen D.W., Sundsfjord J.A., Dickstein K. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Circulation. 93:1996;1963-1969.
25. Yamamoto K., Burnett J.C., Jougasaki M., Nishimura R.A., Bailey K.R., Saito Y., Nakao K., Redfield M.M. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 28:1996;988-994.
26. Stanek B., Frey B., Hülsmann M., et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol. 38:2001;436-442.
27. Dickstein K., Larsen A.I., Bonarjee V., Thoresen M., Aarsland T., Hall C. Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure. Am J Cardiol. 76:1995;679-683.
28. Hall C., Rouleau J.L., Moye L., de Champlain J., Bichet D., Klein M., Sussex B., Packer M., Rouleau J., Arnold M.O. N-terminal proatrial natriuretic factor an independent predictor of long-term prognosis after myocardial infarction . Circulation. 89:1994;1934-1942.
29. Davidson N.C., Naas A.A., Hanson J.K., Kennedy N.SJ., Coutie W.J., Struthers A.D. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol. 77:1996;828-831.
30. A receptor blockade in patients with congestive heart failure. J Am Coll Cardiol. 35:(suppl A):2000;241A.